512 related articles for article (PubMed ID: 32391886)
21. Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy.
Kuo SH; Tasset I; Cheng MM; Diaz A; Pan MK; Lieberman OJ; Hutten SJ; Alcalay RN; Kim S; Ximénez-Embún P; Fan L; Kim D; Ko HS; Yacoubian T; Kanter E; Liu L; Tang G; Muñoz J; Sardi SP; Li A; Gan L; Cuervo AM; Sulzer D
Sci Adv; 2022 Feb; 8(6):eabm6393. PubMed ID: 35138901
[TBL] [Abstract][Full Text] [Related]
22. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
[TBL] [Abstract][Full Text] [Related]
23. Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells.
Dermentzaki G; Dimitriou E; Xilouri M; Michelakakis H; Stefanis L
PLoS One; 2013; 8(4):e60674. PubMed ID: 23580063
[TBL] [Abstract][Full Text] [Related]
24. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine.
Blandini F; Cilia R; Cerri S; Pezzoli G; Schapira AHV; Mullin S; Lanciego JL
Mov Disord; 2019 Jan; 34(1):9-21. PubMed ID: 30589955
[TBL] [Abstract][Full Text] [Related]
25. TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease.
Seo BA; Kim D; Hwang H; Kim MS; Ma SX; Kwon SH; Kweon SH; Wang H; Yoo JM; Choi S; Kwon SH; Kang SU; Kam TI; Kim K; Karuppagounder SS; Kang BG; Lee S; Park H; Kim S; Yan W; Li YS; Kuo SH; Redding-Ochoa J; Pletnikova O; Troncoso JC; Lee G; Mao X; Dawson VL; Dawson TM; Ko HS
Neuron; 2021 Dec; 109(23):3758-3774.e11. PubMed ID: 34644545
[TBL] [Abstract][Full Text] [Related]
26. [GBA mutations and Parkinson's disease].
Wang DX; Xie JX; Song N
Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
[TBL] [Abstract][Full Text] [Related]
27. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
[TBL] [Abstract][Full Text] [Related]
28. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
29. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.
Vieira SRL; Schapira AHV
Free Radic Biol Med; 2021 Nov; 175():42-55. PubMed ID: 34450264
[TBL] [Abstract][Full Text] [Related]
30. Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome.
Ruz C; Barrero FJ; Pelegrina J; Bandrés-Ciga S; Vives F; Duran R
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233303
[TBL] [Abstract][Full Text] [Related]
31. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
32. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
[TBL] [Abstract][Full Text] [Related]
33. Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions.
Mahoney-Crane CL; Viswanathan M; Russell D; Curtiss RAC; Freire J; Bobba SS; Coyle SD; Kandebo M; Yao L; Wan BL; Hatcher NG; Smith SM; Marcus JN; Volpicelli-Daley LA
J Neurosci; 2023 Jan; 43(3):501-521. PubMed ID: 36639889
[TBL] [Abstract][Full Text] [Related]
34. Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains.
Liu G; Chen M; Mi N; Yang W; Li X; Wang P; Yin N; Li Y; Yue F; Chan P; Yu S
Neurobiol Aging; 2015 Sep; 36(9):2649-59. PubMed ID: 26149921
[TBL] [Abstract][Full Text] [Related]
35. Saposin C protects glucocerebrosidase against α-synuclein inhibition.
Yap TL; Gruschus JM; Velayati A; Sidransky E; Lee JC
Biochemistry; 2013 Oct; 52(41):7161-3. PubMed ID: 24070323
[TBL] [Abstract][Full Text] [Related]
36. The role of glucocerebrosidase in Parkinson disease pathogenesis.
Gegg ME; Schapira AHV
FEBS J; 2018 Oct; 285(19):3591-3603. PubMed ID: 29385658
[TBL] [Abstract][Full Text] [Related]
37. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
[TBL] [Abstract][Full Text] [Related]
38. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.
Gegg ME; Menozzi E; Schapira AHV
Neurobiol Dis; 2022 May; 166():105663. PubMed ID: 35183702
[TBL] [Abstract][Full Text] [Related]
39. Glucocerebrosidase dysfunction in neurodegenerative disease.
Brooker SM; Krainc D
Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
[TBL] [Abstract][Full Text] [Related]
40. Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein.
Howe JW; Sortwell CE; Duffy MF; Kemp CJ; Russell CP; Kubik M; Patel P; Luk KC; El-Agnaf OMA; Patterson JR
Parkinsonism Relat Disord; 2021 Aug; 89():41-47. PubMed ID: 34218047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
